PDF(Pubmed)
Abstract：
This study aimed to investigate the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSCLC).
A comprehensive search of PubMed, Web of science, Embase and the Cochrane library was performed to examine the prognostic value of 18F-FDG PET/CT in predicting early immunotherapy response of ICIs in patients with NSCLC. The main outcomes for evaluation were overall survival (OS) and progression-free survival (PFS). Detailed data from each study were extracted and analyzed using STATA 14.0 software.
13 eligible articles were included in this systematic review. Compared to baseline 18F-FDG PET/CT imaging, the pooled hazard ratios (HR) of maximum and mean standardized uptake values SUVmax, SUVmean, MTV and TLG for OS were 0.88 (95% CI: 0.69-1.12), 0.79 (95% CI: 0.50-1.27), 2.10 (95% CI: 1.57-2.82) and 1.58 (95% CI: 1.03-2.44), respectively. The pooled HR of SUVmax, SUVmean, MTV and TLG for PFS were 1.06 (95% CI: 0.68-1.65), 0.66 (95% CI: 0.48-0.90), 1.50 (95% CI: 1.26-1.79), 1.27 (95% CI: 0.92-1.77), respectively. Subgroup analysis showed that high MTV group had shorter OS than low MTV group in both first line group (HR: 1.97, 95% CI: 1.39-2.79) and undefined line group (HR: 2.11, 95% CI: 1.61-2.77). High MTV group also showed a shorter PFS in first line group (HR: 1.85, 95% CI: 1.28-2.68), and low TLG group had a longer OS in undefined group (HR: 1.37, 95% CI: 1.00-1.86). No significant differences were in other subgroup analysis.
Baseline MTV and TLG may have predictive value and should be prospectively studied in clinical trials. Baseline SUVmax and SUVmean may not be appropriate prognostic markers in advanced or metastatic NSCLC patients treated with ICIs.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=323906, identifier CRD42022323906.
A comprehensive search of PubMed, Web of science, Embase and the Cochrane library was performed to examine the prognostic value of 18F-FDG PET/CT in predicting early immunotherapy response of ICIs in patients with NSCLC. The main outcomes for evaluation were overall survival (OS) and progression-free survival (PFS). Detailed data from each study were extracted and analyzed using STATA 14.0 software.
13 eligible articles were included in this systematic review. Compared to baseline 18F-FDG PET/CT imaging, the pooled hazard ratios (HR) of maximum and mean standardized uptake values SUVmax, SUVmean, MTV and TLG for OS were 0.88 (95% CI: 0.69-1.12), 0.79 (95% CI: 0.50-1.27), 2.10 (95% CI: 1.57-2.82) and 1.58 (95% CI: 1.03-2.44), respectively. The pooled HR of SUVmax, SUVmean, MTV and TLG for PFS were 1.06 (95% CI: 0.68-1.65), 0.66 (95% CI: 0.48-0.90), 1.50 (95% CI: 1.26-1.79), 1.27 (95% CI: 0.92-1.77), respectively. Subgroup analysis showed that high MTV group had shorter OS than low MTV group in both first line group (HR: 1.97, 95% CI: 1.39-2.79) and undefined line group (HR: 2.11, 95% CI: 1.61-2.77). High MTV group also showed a shorter PFS in first line group (HR: 1.85, 95% CI: 1.28-2.68), and low TLG group had a longer OS in undefined group (HR: 1.37, 95% CI: 1.00-1.86). No significant differences were in other subgroup analysis.
Baseline MTV and TLG may have predictive value and should be prospectively studied in clinical trials. Baseline SUVmax and SUVmean may not be appropriate prognostic markers in advanced or metastatic NSCLC patients treated with ICIs.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=323906, identifier CRD42022323906.
摘要：
本研究旨在探讨18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-FDGPET/CT）在预测晚期或转移性非小细胞肺癌（NSCLC）患者免疫检查点抑制剂（ICIs）早期免疫治疗反应中的价值。
全面搜索PubMed,WebofScience,Embase和Cochrane文库用于检查18F-FDGPET/CT在预测NSCLC患者ICIs早期免疫治疗反应中的预后价值。评估的主要结果是总生存期（OS）和无进展生存期（PFS）。使用STATA14.0软件提取和分析来自每个研究的详细数据。
本系统综述包括13篇符合条件的文章。与基线18F-FDGPET/CT成像相比，最大和平均标准化摄取值SUVmax的汇总风险比(HR)，Suvmean,OS的MTV和TLG为0.88（95%CI：0.69-1.12），0.79（95%CI：0.50-1.27），2.10（95%CI：1.57-2.82）和1.58（95%CI：1.03-2.44），分别。SUVmax的合并HR，Suvmean,PFS的MTV和TLG为1.06（95％CI：0.68-1.65），0.66（95%CI：0.48-0.90），1.50（95%CI：1.26-1.79），1.27（95%CI：0.92-1.77），分别。亚组分析显示，一线组（HR：1.97，95％CI：1.39-2.79）和未定义线组（HR：2.11，95％CI：1.61-2.77）中，高MTV组的OS均短于低MTV组。高MTV组一线组PFS较短(HR:1.85,95%CI:1.28-2.68),而低TLG组的OS在未定义组中更长(HR:1.37,95%CI:1.00-1.86)。其他亚组分析差异无统计学意义。基线MTV和TLG可能具有预测价值，应在临床试验中进行前瞻性研究。基线SUVmax和SUVmean可能不是ICIs治疗的晚期或转移性NSCLC患者的适当预后指标。
https://www。crd.约克。AC.uk/prospro/display_record.php?RecordID=323906，标识符CRD4202223906。
全面搜索PubMed,WebofScience,Embase和Cochrane文库用于检查18F-FDGPET/CT在预测NSCLC患者ICIs早期免疫治疗反应中的预后价值。评估的主要结果是总生存期（OS）和无进展生存期（PFS）。使用STATA14.0软件提取和分析来自每个研究的详细数据。
本系统综述包括13篇符合条件的文章。与基线18F-FDGPET/CT成像相比，最大和平均标准化摄取值SUVmax的汇总风险比(HR)，Suvmean,OS的MTV和TLG为0.88（95%CI：0.69-1.12），0.79（95%CI：0.50-1.27），2.10（95%CI：1.57-2.82）和1.58（95%CI：1.03-2.44），分别。SUVmax的合并HR，Suvmean,PFS的MTV和TLG为1.06（95％CI：0.68-1.65），0.66（95%CI：0.48-0.90），1.50（95%CI：1.26-1.79），1.27（95%CI：0.92-1.77），分别。亚组分析显示，一线组（HR：1.97，95％CI：1.39-2.79）和未定义线组（HR：2.11，95％CI：1.61-2.77）中，高MTV组的OS均短于低MTV组。高MTV组一线组PFS较短(HR:1.85,95%CI:1.28-2.68),而低TLG组的OS在未定义组中更长(HR:1.37,95%CI:1.00-1.86)。其他亚组分析差异无统计学意义。基线MTV和TLG可能具有预测价值，应在临床试验中进行前瞻性研究。基线SUVmax和SUVmean可能不是ICIs治疗的晚期或转移性NSCLC患者的适当预后指标。
https://www。crd.约克。AC.uk/prospro/display_record.php?RecordID=323906，标识符CRD4202223906。
